Therapeutic potential of GSK-J4, a histone demethylase KDM6B/JMJD3 inhibitor, for acute myeloid leukemiaYunan Li(Chinese Academy of Medical Sciences & Peking Union Medical College), Yuan Zhou(Chinese Academy of Medical Sciences & Peking Union Medical College)Journal of Cancer Research and Clinical OncologyMarch 28, 201810.1007/s00432-018-2631-7Cited by 111SaveCiteExport RISWatch citationsRelated PapersThe miR-106b∼25 cluster promotes bypass of doxorubicin-induced senescence and increase in motility and invasion by targeting the E-cadherin transcriptional activator EP300|Cell Death and Differentiation|2013|90Upregulation of miR-99a is associated with poor prognosis of acute myeloid leukemia and promotes myeloid leukemia cell expansion|Oncotarget|2016|36